• Pharmascience completed a project aimed at modernizing its Montréal facilities and boosting its production capacity. Estimated at $55.7 million, the project created 65 jobs.

• Nestle Skin Health invested $46 million to expand its medical division, Galderma, in the Greater Montréal Area. The company expects to boost its plant’s production capacity and add 65 employees to the current tally of 315.
• Medtronic will move its ablation device production operations from California to its Montréal plant. This expansion project, assessed at $10.7 million, will create 47 jobs over the next three years.

• Medicago, a major Canadian biotechnology company and global leader in vaccine and herbal treatment creation and production, chose to establish a new production facility in Québec City. The $245 million project will be completed by 2019.
• Green Cross Biotherapeutics, a South Korean biopharmaceutical company, has announced the construction of a plasma fractionation plant in Montréal. A total of $375 million will be invested in the project.

“North America is a huge market for intravenous immunoglobulin (IVIG), accounting for over 40% of the global plasma product market. Québec government authorities have been very helpful, bringing together strategic partners in Québec’s blood products sector and providing us the information we need to make sound investment decisions.

We’re eager to start producing safe, high-quality drugs in Québec.”

- Young-Ho Kim, President, Green Cross Biotherapeutics

• Servier, the second largest French pharmaceutical laboratory, inaugurated a clinical research centre of excellence in Laval. The facility, which cost $16.3 million and covers an area of 2,780 m², was built to help design and develop Servier’s international clinical research. Many major therapeutic areas will be studied at the lab, including cardiovascular disease, cancerology and neuropsychiatry.